US · Healthcare · Biotechnology
EPS came in at -1.52 against a street estimate of -1.60 — a beat of 5.0%.
Analysts rate Vera Therapeutics Inc a strong buy (13 buy, 2 hold, 0 sell out of 15) with an average price target of $73.79.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.98% |
| venBio Select Advisor LLC | 7.94% |
| State Street Corp | 5.76% |
| T. Rowe Price Associates, Inc. | 5.57% |
| Deep Track Capital, LP | 5.55% |
| Deerfield Management Co | 5.43% |
| Kynam Capital Management, LP | 4.01% |
| Morgan Stanley - Brokerage Accounts | 3.88% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Q3 2026 product revenue was $10.277 million; there was no product revenue in Q3 2025. • Nine-month 2026 product revenue was $10.2 | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net product revenue was $10.3 million, versus no product revenue in Q3 2025. • Net loss was $93.7 million, or $1.30 per s | 2026-11-05 |
| Reg FD disclosure · Q3 2026 VERA THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Drug candidate: TRUTAKNA® (atacicept-vymj) for primary IgA nephropathy (IgAN) • Trial: ORIG | 2026-09-15 |
| Quarterly report · Q2 2026 VERA THERAPEUTICS, INC. – 10-Q SUMMARY (JUNE 30, 2026) HEADLINE NUMBERS • Cash and Marketable Securities: $499.2 million as of June 30, 2026 (down f | 2026-08-10 |
| Results announced · Q3 2026 VERA THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 net loss: $109.5 million (or $1.52 per share), compared to $76.5 million loss | 2026-08-10 |
| Board / officer change · Q3 2026 VERA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Vera Therapeutics, Inc. (Nasdaq: VERA) • Filing Date: July 9, 2026 • Headquarters: | 2026-07-09 |
| Company announcement · Q3 2026 VERA THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Report Date: July 7, 2026 • Company: Vera Therapeutics, Inc. (Nasdaq: VERA) • Headquarters: | 2026-07-07 |
| Company announcement · Q2 2026 VERA THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • No financial metrics provided in this 8-K filing • Company reports regulatory milestone ann | 2026-06-02 |
Readable in the app.
| Announcement | Date |
|---|---|
| FDA grants accelerated approval for TRUTAKNA in IgA nephropathy patients Vera Therapeutics received FDA accelerated approval for TRUTAKNA, a new kidney disease treatment for IgA nephropathy (IgAN), marking the company's transition from development to commercial s | 2026-08-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vera Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.